The increase was primarily due to a $36.0 million increase in salaries and other employee-related expenses due to increased headcount; a $18.0 million increase in stock-based compensation expense related to increased headcount and introducing retirement benefit provisions in our equity compensation program in 2026; a $9.9 million increase in legal fees and other administrative expenses; and a $6.1 million increase in

filing / Aug 5, 2026 / receipt

The increase was primarily due to a $51.9 million increase in stock-based compensation expense related to increased headcount and introducing retirement benefit provisions in our equity compensation program in 2026; a $51.5 million increase in salaries and other employee-related expenses due to increased headcount; a $13.1 million increase in commercial preparation expenses; and a $16.7 million increase in legal fees

filing / Aug 5, 2026 / receipt

As our development and commercialization plans and strategies develop, and as we continue to operate as a public company with expanding global operations, we expect to need additional personnel across our organization and in multiple jurisdictions.

filing / Aug 5, 2026 / receipt

healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and requiring substitutions of generic products and/or biosimilars.

filing / Aug 5, 2026 / receipt

Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available, could have a material adverse effect on the Company’s ability to achieve its business objectives.

filing / Aug 5, 2026 / receipt

The increase was primarily due to a $34.0 million increase in stock-based compensation expense; a $15.5 million increase in salaries and other employee-related expenses due to increased headcount; a $7.0 million increase in commercial preparation expenses; a $5.8 million increase in legal and accounting fees; a $2.9 million increase in facilities and other allocated expenses as a result of higher rent, utilities and

filing / May 6, 2026 / receipt

We expect our general and administrative expenses to increase for the foreseeable future due to anticipated increases in operating and commercial preparation activities, which may result in increases in personnel-related costs associated with increased headcount, other administrative and professional services, and related overhead needed to support these efforts.

filing / May 6, 2026 / receipt

As our development and commercialization plans and strategies develop, and as we continue to operate as a public company with expanding global operations, we expect to need additional personnel across our organization and in multiple jurisdictions.

filing / May 6, 2026 / receipt

healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and requiring substitutions of generic products and/or biosimilars.

filing / May 6, 2026 / receipt

Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available, could have a material adverse effect on the Company’s ability to achieve its business objectives.

filing / May 6, 2026 / receipt

Machine Learning Scientist II

company_statement / Sep 15, 2026 / receipt

Senior Machine Learning Scientist I

company_statement / Sep 9, 2026 / receipt